GSK: EU indication extended for RSV vaccine

(CercleFinance.com) - GSK has announced that the European Commission has approved its Arexvy respiratory syncytial virus (RSV) vaccine for adults aged 50 to 59 at increased risk of lower respiratory tract disease (LRTD).


Since June 2023, this vaccine has already been approved for adults aged 60 and over in Europe, affecting around 20 million adults in this new age group in Europe.

GSK welcomes this approval, underlining the importance of extending protection against RSV.

The approval is based on positive results from a Phase III clinical trial on the safety and efficacy of the vaccine in this age group.


Copyright (c) 2024 CercleFinance.com. All rights reserved.